These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 16912295)

  • 1. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
    Cho SJ; Drechsler H; Burke RC; Arens MQ; Powderly W; Davidson NO
    J Virol; 2006 Feb; 80(4):2069-72. PubMed ID: 16439564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
    Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
    World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
    Jost S; Turelli P; Mangeat B; Protzer U; Trono D
    J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dancin' deaminase.
    Harris RS; Matsuo H
    Nat Struct Mol Biol; 2006 May; 13(5):380-1. PubMed ID: 16738602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
    Langlois MA; Beale RC; Conticello SG; Neuberger MS
    Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins.
    Huthoff H; Malim MH
    Virology; 2005 Apr; 334(2):147-53. PubMed ID: 15780864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
    Wang X; Dolan PT; Dang Y; Zheng YH
    J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Liddament MT; Brown WL; Schumacher AJ; Harris RS
    Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome.
    Ebrahimi D; Anwar F; Davenport MP
    Retrovirology; 2012 Dec; 9():113. PubMed ID: 23256516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC-mediated editing of viral RNA.
    Bishop KN; Holmes RK; Sheehy AM; Malim MH
    Science; 2004 Jul; 305(5684):645. PubMed ID: 15286366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.